Anzahl der Publikationen: 3
Zeitschriftenartikel
Patil, Shivaprasad; Tawk, Bouchra; Grosser, Marianne; Lohaus, Fabian; Gudziol, Volker; Kemper, Max; Nowak, Alexander; Haim, Dominik; Tinhofer, Inge; Budach, Volker; Guberina, Maja; Stuschke, Martin; Balermpas, Panagiotis; Roedel, Claus; Schaefer, Henning; Grosu, Anca-Ligia; Abdollahi, Amir; Debus, Juergen; Ganswindt, Ute; Belka, Claus; Pigorsch, Steffi; Combs, Stephanie E.; Boeke, Simon; Zips, Daniel; Baretton, Gustavo B.; Baumann, Michael; Krause, Mechthild; Loeck, Steffen und Linge, Annett
(2022):
Analyses of molecular subtypes and their association to mechanisms of radioresistance in patients with HPV-negative HNSCC treated by postoperative radiochemotherapy.
In: Radiotherapy and Oncology, Bd. 167: S. 300-307
Patil, Shivaprasad; Linge, Annett; Grosser, Marianne; Lohaus, Fabian; Gudziol, Volker; Kemper, Max; Nowak, Alexander; Haim, Dominik; Tinhofer, Inge; Budach, Volker; Guberina, Maja; Stuschke, Martin; Balermpas, Panagiotis; Roedel, Claus; Schaefer, Henning; Grosu, Anca-Ligia; Abdollahi, Amir; Debus, Juergen; Ganswindt, Ute; Belka, Claus; Pigorsch, Steffi; Combs, Stephanie E.; Boeke, Simon; Zips, Daniel; Baretton, Gustavo B.; Baumann, Michael; Krause, Mechthild und Loeck, Steffen
(2022):
Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy.
In: Radiotherapy and Oncology, Bd. 171: S. 91-100
Patil, Shivaprasad; Linge, Annett; Hiepe, Hannah; Grosser, Marianne; Lohaus, Fabian; Gudziol, Volker; Kemper, Max; Nowak, Alexander; Haim, Dominik; Tinhofer, Inge; Budach, Volker; Guberina, Maja; Stuschke, Martin; Balermpas, Panagiotis; Grun, Jens von der; Schafer, Henning; Grosu, Anca-Ligia; Abdollahi, Amir; Debus, Jürgen; Ganswindt, Ute; Belka, Claus; Pigorsch, Steffi; Combs, Stephanie E.; Boeke, Simon; Zips, Daniel; Johrens, Korinna; Baretton, Gustavo B.; Baumann, Michael; Krause, Mechthild und Lock, Steffen
(2022):
A Novel 2-Metagene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT.
In: Cancers, Bd. 14, Nr. 12, 3031
Diese Liste wurde am
Sat Dec 21 23:45:36 2024 CET
erstellt.